Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac.

Trial Profile

Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2013

At a glance

  • Drugs Meningococcal vaccine group B OMV (Primary)
  • Indications Meningococcal group B infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 14 Apr 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 May 2008 Status changed from recruiting to in prgoress, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top